ESMO 2022

My highlights of ESMO22

Consolidating data from prospective studies

Dose dense is better

Hand cooling and compression both effective in preventing chemotherapy-induced peripheral neuropathy

Endocrine response in eBC

DD is the champion!

Dose-dense therapy is beneficial for all patients

Long-term data on dose density therapy in chemotherapy

QoL and longterm toxicity

Simple and cheap surgical technique may impact survival in early breast cancer

Immuntherapy only for low risk patients?

Dose-dense standard of care is the optimal care

Reduction of peripheral neuropathy with taxane therapy

Roadmap for the adjuvant setting

Chłodzenie rąk i terapia kompresyjna skutecznie obniżają ryzyko neuropatii obwodowej po leczeniu taksanami

Rosta i tania technika chirurgiczna może wpływać na czas przeżycia we wczesnym raku piersi

Schéma dose-dense bénéfique pour toutes les patientes

Datele trialurilor se consolideata

I miei punti salienti di ESMO22

Il vincitore e’ il dose dense!!

DATA: Still open questions on the optimal duration of extended adjuvant endocrine therapy? Greatest effect in the endocrine sensitive population. N+ higher risk. Contralateral disease with longer benefit

How to deal with the negative SERD data?

Tailoring Adjuvant Therapy

Unmeet needs and my wishes for 2022!

Status update - adjuvant IO. Are TILs prognostic?

Dose-dense CT Efficacy confirmed in the Nodal+ ER+ population. Do all luminal patients benefit? What about secondary malignancies?

Who needs Chemo? Who does not? Is OFS plus endocrine Therapy sufficient without prior Chemo? Response Assessment before surgery

HER2+ and still without chemotherapy

My highlights of ESMO22

Update on biomarkers on ADCs of the DAISY trial

Discontinued development

ADC after ADC - is there any orientation?

Sacituzumab govitecan for everybody!

New treatment option for heavily pre-treated patients with ER+ MBC

OS not significant, but re-assuring new data

The third in the bunch

VEX has no place in chemotherapy of metastatic breast cancer

TROPiCS-02 highlights

Survival benefit in endocrine sensitive patients

Interim analysis shows promising data on Abema in the 1st Line

Another option for heavily pre-treated HR+ advanced breast cancer patients

Endocrine-based therapy may prove more effective than chemo in “triple-positive” advanced breast cancer

New data re-inforces SG as a new option pre-treated HR+/HER2- patients

Survival benefit from SG in mBC

CDK4/6i could be an option for selected ER+/HER2+ disease

SG is a novel treatment option for HR+/HER2- disease

Negative and yet positive?!

More therapy options for patients with HR+, HER2+ disease

Exciting data, but Phase 3 studies are needed

Nouvelle option thérapeutique pour les patientes lourdement prétraitées RH+ HER2-

Survie globale pas encore significative statistiquement mais données rassurantes

Leczenie zaawansowanych raków „potrójnie dodatnich” oparte na hormonoterapii może okazać się bardziej skuteczne niż chemioterapia

Nuove opzioni di trattamento personalizzate per pazienti con tumore mammarioHR+/HER2+

Sacituzumab Govitecan: Un farmaco per tutte?

TROPiCS-02 highlights

Sopravvivenza globale nello studio MONARCH3

SG come nuova opzione di cura Per pazienti con tumore mammario HR+/HER2-

Nouvelles données des analyses expolratoires dans l’étude DAISY

I miei punti salienti di ESMO22

SG confirms benefit in OS, PFS, ORR, QoL, the new 2nd line Standard of Care? What will be the treatment sequence? A European, US and Asian Perspective

Monarch-3: strong OS Survival; DAWNA-2: PFS in line with existing CDK4/6i; monarcHER: a chemo-free treatment option

ADC efficacy in perspective: SG overall survival benefit, efficacy comparable for HER2- and HER2low. ADC sequencing could become an option. We need data for earlier settings.

SERDs: equal PFS benefit vs. endocrine therapy; adjuvant data to be expected

Interim OS Data & PFS Update for Abemaciclib hint towards final consistent OS benefit. We need to focus on resistance drivers.

CDK4/6i plus Trastuzumab – a possible chemo-free option for triple positive patients?

ADAURA Update - preventing relapse or just delaying it?

INCREASE - to good to be true?

Long term follow-up of ADAURA trial

ADAURA revisited

Is OS really needed?

Liquid biopsy monitoring of EGFR-mutant lung cancer patients before and after surgery

Osimertinib - curing or delaying relapse?

Concurrent preoperative IO/CRT in early lung cancer

Neoadjuvant strategies for PD-L1 < 1 %

Window for treatment selection

Pollution and lung cancer - one mechanism revealed

Double IO + chemoradiotherapy - is it feasible in borderline resectable stage III NSCLC patients?

Osimertinib stays standard adjuvant

Liquid biopsie monitoring van patiënten met een EGFR mutatie voor en na chirurgie

Pollution et cancer du poumon - un mécanisme mis en évidence

Osimertinib bleibt Standard adjuvant

Langzeitdaten ADAURA

Eine Plattform für "take the winner"-Strategie

ADAURA revisited

Osimertinib: una cura o ritarda la ripresa di malattia?

Dubbele immunotherapie plus chemoradiotherapie - is het haalbaar bij patiënten met borderline resectable stadium III NSCLC?

DFS matters!

Important data on borderline resectable patients

Long term follow-up of KEYNOTE-189 and KEYNOTE-407

Sotorasib vs. Docetaxel in mKRAS G12C

Can IO be discontinued?

Real-world data on Atezolizumab

A new step in treatment of KRAS G12C mutant NSCLC

Atezolizumab better than vinorelbin in reduced performance status

One more brick in the KRAS G12C wall

Liquid biopsy monitoring in treatment decisions

If you don't look, vou don't find - once you found it, you'll treat it!

New immunotherapy options for pts. ineligible to 1st line platinum therapy

Emerging IO mono options in the first line

Sotorasib: sweet and sour results

Induction chemoimmunotherapy in borderline resectability?

Duration of immunotherapy : Stop and go strategy for Nivo/Ipi

Immunotherapy in unfit population? Perhaps...

HER2 - the next actionable mutation in lung cancer?

New therapy combination after progression on 1L osimertinib

Chemoimmunotherapy - improvement of survival after 5 years

Pneumonitis and T-DXd

Preview on lung cancer highlights

5 years of chemoimmunotherapy: solid grounded

Cemiplimab beyond progression?

Poseidon and STK11/KEAP

The journey at KRAS G12C continues

Question about timing and duration of immunotherapy still unanswered

Sotorasib - a new standard of care?

Is shorter immunotherapy equally effective and less physically demanding?

DESTINY-Lung02 - better than the original?

Can we finally treat poor prognostic patients with immunotherapy?

5-year update on 1st line chemoimmunotherapy

5-year data on survival under immunotherapy

Durée de l'immunothérapie : stratégie Stop and Go pour l 'association Nivo/Ipi

Liquid Biopsy Monitoring zur Therapiesteuerung

Chimio-immunothérapie - amélioration de la survie après 5 ans

Chemo-IO-Induktion bei grenzwertiger Resektabilität?

Atezo besser als Vino bei PS2-3

Une nouvelle étape dans le traitement du CBNPC KRAS G12C muté

Die Reise bei KRAS G12C geht weiter

Neue Option der IO-Therapie in der Erstlinie

Sotorasib vs. Docetaxel bei mKRAS G12C

5 Jahre Chemo-Immuntherapie: starker Effekt

Les études incontournables à l’ESMO 2022

Kunnen we eindelijk patiënten met een slechte prognose behandelen met immunotherapie?

Cemiplimab beyond progression?

5-Jahresüberleben mit Immuntherapie

Un mattone in piu' nel muro del KRAS G12C

Poseidon und STK11/KEAP

Una nueva opción de tratamiento con IO en pacientes no tributarios de 1L con platino

Kürzere Immuntherapie gleich effektiv aber weniger belastend?

Se non lo cerchi non lo troiv. Quando lo hai trovato, trattalo

Neue Therapiekombination in der Resistenz nach Osimertinib

Resultados Agridulces de Sotorasib

Pneumonitis und T-DXd

Kann IO pausiert werden?

Données de vie réelle avec l’atezolizumab

IO-IO neoadjuvant bei PD-L1 neg.

Immunoterapia nella popolazione non fit: forse

Novel data and long-term efficacy of chemo-IO in mNSCLC

New strategies in immunotherapy

Heterogenity in the genetic landscape - little progress in molecular alterations

A positive study! With a question mark?

Two negative studies question adjuvant approach in RCC

New combo - triplet therapy for kidney cancer

Exciting data for high-risk patients: is this the start of a new era?

Brief highlights about RCC & urothelial cancer from ESMO22

Adjuvant CPI in kidney cancer – 2 phase III trials with novel insights!

Immune-based peri-operative treatment in RCC: What went wrong?

More questions being raised

Adjuvant Immuntherapy in kidney cancer

Place of triplet therapy

No value of IPI/Nivo in the adjuvant setting.

News in terms of adjuvant

Tratamiento perioperatorio con immunoterapia en cáncer renal: Que ha fallado?

Terapia triple para cancer renales

Μηνύματα από το ESMO22 για τον καρκίνο του νεφρού

Inmunoterapia adyuvante en el cancer renales

Immunomodulation in combination with checkpointinhibiton

Shedding light on TKI/Checkpointinhibitor combinations

Adjuvant immunotherapy options in RCC - what do we learn from ESMO22 data for the adjuvant setting?

Therapy combinations in RCC - what is the role of triplet therapy?

EV + pembrolizumab in cisplatin-ineligible patients

EV + Pembro with excellent response rates

Brief highlights about RCC & urothelial cancer from ESMO22

Μηνύματα από το ESMO22 για τον ουροθηλιακό καρκίνο

Biomarker exploration in urothelial cancer - finding the right assay for the right drug!

Promising data, but beware of toxicity

Adjuvant and neoadjuvant therapy approaches in urothelial cancer

In older vulnerable - less is more

PSA at 8-months as a biomarker

Further evaluation of PSA correlates

ADT + ENZA better choice than monotherapy

IO + PARP without benefit in the allcomer situation

Should intensification of ADT be considered in high-risk biochemically relapsed PC?

Length of hormone therapy after radiation

Radicals - ADT & Radiotherapy

ADCs - a possible therapeutic approach

Optimizing cabazitaxel chemotherapy

QoL data from ARASENS triplet therapy study mHRPC

Combination of olaparib leads to promising results

Triplet therapy with darolutamide in prostate cancer

Genetic testing before PARP therapy is useful

Biomarker data for better patients selection

Update on the PROpel study

Cabazitaxel better tolerated in elderly men

IM arbiraterone decanoate might demonstrate superior therapeutic index and tolerability

Uppdatering i PROpel studien

Livskvalitetsuppföljning i ARASENS studien

PSA efter 8 månader i PEACE-1 studien som biomarkör

Intimate partner violence in cancer patients

Addition of CPI to Radiochemotherapy in LA-HNSCC?

New group of substances for rare diseases

IAP-inhibition – comming game changer in LA-HNSCC Radiochemotherapy

TILs - Fashion is the eternal return of the old

Novel approach von Biontech towards Cancer – game changing potential?!